A Phase 2 interventional study of VX-745 and placebo in Alzheimer Disease, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-06-22.
Sponsored by University Hospital, Toulouse · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Alzheimer Disease by University Hospital, Toulouse — 4 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · University Hospital, Toulouse.
Among the 17 studies in Alzheimer Disease by University Hospital, Toulouse, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2018, is one of 2 in phase 2, and was the 9th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →4 of the 17 studies in Alzheimer Disease by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 50–85
University Hospital, Toulouse · Sites in France
Ages 60–100 · Healthy volunteers
University Hospital, Toulouse · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Toulouse · Sites in France
Ages 18–100
By country, each count listing its studies:
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 1
First in 2003; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 120 across the 14 interventional studies, 1,000 across the 3 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Alzheimer Disease by University Hospital, Toulouse, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
For this project, neflamapimod and placebo will be provided free of charge by the EIP company (www.eippharma.com). Neflamapimod is currently tested in 2 clinical trials in AD, one in Europe (The Netherlands) and one in the USA (clinical trials.gov/VX-745). The company commenced in May 2015 dosing in two phase 2a clinical studies in patients with Early AD: one in the Netherlands that is focused on PET amyloid imaging as the primary biomarker of drug effect, and one in the US (California) that is focused on Cerebrospinal fluid (CSF) evaluation to determine CSF drug concentrations and effects on inflammatory markers and disease biomarkers. Pharmacokinetic evaluation in these patients has demonstrated blood drug concentration levels in the predicted therapeutic range; and importantly, the data from the US study demonstrate that the drug achieves target drug concentrations in CSF, thus confirming the drug robustly enters the brain in humans.
The present project offers us a unique chance to test this promising drug in AD patients. The aim of the study is to focus on PET neuroinflammation imaging as the primary biomarker of this drug effect. The chosen biomarker for imaging neuroinflammation in patients is [1 8F]-DPA714.
The present project is an intervention proof of concept study to test the efficacy of neflamapimod in a population of AD patients at an early stage.
To track the impact of this drug in patients, the investigators will use an innovative radiotracer, [18F]DPA-714, as a promising ligand of microglial activation targeting the translocator protein (TSPO), specific of microglial activation. The use of [18F]DPA-714 will allow to monitor the evolution of neuroinflammation in patients as a function of treatment. The main objective will be to compare the level of inflammation using the [18F]DPA-714 in neflamapimod and placebo groups after 12 weeks of treatment. Blood and cerebrospinal fluid (CSF) samples and magnetic resonance imaging (MRI) will also be collected to assess inflammation markers and brain structure respectively in these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A group of 40 AD patients at an early stage (prodromal) will be recruited. Patient's recruitment will follow the most recent research criteria for AD in its "typical form" (Dubois, Feldman et al. 2014):
Exclusion Criteria:
Evidence of neurodegenerative disease other than AD
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the present study, VX-745 will be given at the dosage of 40 mg twice a day (1 tab. of 40 mg, twice), orally for 12 weeks
Drug: VX-745
In the present study, placebo will be given twice a day (1 tab. , twice), orally for 12 weeks
Drug: placebo
active drug capsules
Also known as: neflamapimod
placebo capsules
brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV)
To track the impact of this drug in patients, investigators will use an innovative radiotracer, \[18F\]DPA-714, as a promising ligand of microglial activation targeting the translocator protein (TSPO), specific of microglial activation. The use of \[18F\]DPA-714 will allow us to monitor the evolution of neuroinflammation in patients as a function of treatment. the main objective will be to compare the level of inflammation using the \[18F\]DPA-714 in neflamapimod and placebo. Regional cortical DPA-714 mean SUV will be measured in each subject using a Matlab (The MathWorks®) script. Mean global SUVs will be calculated
Time frame: 3 month
brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV) 2
SUVs in the five lobes will be calculated.
Time frame: 3 month
brain inflammation assessed by [18F]-DPA714, Standard Uptake Value (SUV)3
SUVs in specific regions of interest (ROIs: orbitofrontal, anterior cingulate, posterior cingulate and precuneus) will be calculated.
Time frame: 3 month
Neuropsychological assessment to assess the following cognitive functions 1:
Memory: Rey Figure
Time frame: 3 month
Neuropsychological assessment to assess the following cognitive functions 2:
Memory: DMS 48,
Time frame: 3 month
Neuropsychological assessment to assess the following cognitive functions 1.1:
Language: confrontation naming (Gremots),
Time frame: 3 month
Neuropsychological assessment to assess the following cognitive functions 2.2:
Language: FAS fluencies,
Time frame: 3 month
Neuropsychological assessment to assess the following cognitive functions 3:
o Attention and executive functions: D2
Time frame: 3 month
Neuropsychological assessment to assess the following cognitive functions 4:
o Attention and executive functions: TEA
Time frame: 3 month
Neuropsychological assessment to assess the following cognitive functions 5:
o Attention and executive functions: SDMT WAIS
Time frame: 3 month
Blood and CSF biomarkers of inflammation1
ApoE phenotype
Time frame: 3 month
Blood and CSF biomarkers of inflammation 2
TSPO phenotype,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 3
TNFa,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 4
IL-1b,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 5
IFNg
Time frame: 3 month
Blood and CSF biomarkers of inflammation 6
IL-12
Time frame: 3 month
Blood and CSF biomarkers of inflammation 7
IFNa/b
Time frame: 3 month
Blood and CSF biomarkers of inflammation 8
IL-10
Time frame: 3 month
Blood and CSF biomarkers of inflammation 9
IL-6
Time frame: 3 month
Blood and CSF biomarkers of inflammation 10
IL-8,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 11
MCP-1,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 12
GM-CSF
Time frame: 3 month
Blood and CSF biomarkers of inflammation 13
IL-27
Time frame: 3 month
Blood and CSF biomarkers of inflammation 14
chimiokines receptors,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 15
PD-1,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 16
CD14/16
Time frame: 3 month
Blood and CSF biomarkers of inflammation 17
p-tau,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 18
abéta42,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 19
Abeta40,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 20
cells count
Time frame: 3 month
Blood and CSF biomarkers of inflammation 21
TNFa
Time frame: 3 month
Blood and CSF biomarkers of inflammation 22
IL-1b
Time frame: 3 month
Blood and CSF biomarkers of inflammation 23
IL-12
Time frame: 3 month
Blood and CSF biomarkers of inflammation 24
MCP-1
Time frame: 3 month
Blood and CSF biomarkers of inflammation 25
GM-CSF
Time frame: 3 month
Blood and CSF biomarkers of inflammation 26
IL-27,
Time frame: 3 month
Blood and CSF biomarkers of inflammation 27
PD-1
Time frame: 3 month
Blood and CSF biomarkers of inflammation 28
CD14/16
Time frame: 3 month
Plan to share: No
Ran from Oct 2018 to primary completion in Apr 2021, 30 months.
Of 127 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's 30 months is below that.
Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VX-745
University Hospital, Toulouse →